Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.71 |
| ▸ | DRD2 | P14416 | 7/20 | 0.56 |
| ▸ | DRD3 | P35462 | 7/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30813284 | 1.00 | HRH4 (0.74) | HRH4HRH3DRD2DRD3LOXL2 | |
| SCHEMBL4896453 | 0.98 | HRH4 (0.72) | HRH4HRH3DRD2DRD3LOXL2 | |
| SCHEMBL31010169 | 0.98 | HRH4 (0.72) | HRH4HRH3DRD2DRD3LOXL2 | |
| SCHEMBL5442333 | 0.87 | HRH4 (0.70) | HRH4HRH3DRD2DRD3LOXL2 | |
| SCHEMBL29744181 | 0.87 | HRH4 (0.70) | HRH4HRH3DRD2DRD3LOXL2 | |
| SCHEMBL8681808 | 0.85 | HRH4 (0.73) | HRH4HRH3DRD2DRD3 | |
| SCHEMBL13499601 | 0.85 | HRH4 (1.00) | HRH4HRH3DRD2DRD3CHRNA7 | |
| SCHEMBL31061131 | 0.83 | HRH3 (1.00) | HRH4HRH3DRD2DRD3LOXL2 | |
| SCHEMBL23964155 | 0.83 | HRH4 (0.78) | HRH4HRH3DRD2DRD3CHRNA7 | |
| SCHEMBL8682915 | 0.83 | HRH4 (0.69) | HRH4HRH3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| EP-3931188-B1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-30 | — | — | EP | disclosed |
| EP-3931188-B1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| CN-113474340-A | Novel isoindolinone substituted indoles and derivatives as RAS inhibitors | 勃林格殷格翰国际有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-6818639-B2 | COMBINATION OF A 5-HT2C RECEPTOR AGONIST AND A 5-HT6 RECEPTOR ANTAGONIST, OR A SALT, ENANTIOMER OR PRODRUG FORM | BIOVITRUM AB (SE) | 2004-11-16 | — | — | US | disclosed |
| EP-1301476-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-06-06 | — | — | US | disclosed |
| WO-2002008178-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2002-01-31 | — | — | WO | disclosed |
| WO-2000037074-A1 | MUTILIN 14-ESTER DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-06-29 | — | — | WO | disclosed |
| EP-0695301-A1 | INDOLE DERIVATIVES AS 5-H1-LIKE AGONISTS FOR USE IN MIGRAINE | PFIZER LTD (GB) | 1996-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | NRAS, KRAS, RASSF5 | HRH4 1330/4885HRH3 1753/4885DRD2 1253/4885 |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | NRAS, RASSF5, KRAS | HRH4 1268/4885HRH3 1816/4885DRD2 1107/4885 |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | HTR6, HTR5A, HTR2C | HRH4 98/4885HRH3 250/4885DRD2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.